Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 10 2021 - 1:30PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”)
today announced that members of the senior management team will
participate in the H.C. Wainwright & Co. 23rd Annual Global
Investment Conference, September 13-15, 2021. The Aurinia
presentation will be available on-demand beginning September 13,
2021 at 3 pm ET.
The audio webcast is available here. Interested parties can also
register and access the presentation under "News/Events” through
the “Investors” section of the Aurinia corporate website at
www.auriniapharma.com. A replay of the webcast will be available on
Aurinia’s website.
ABOUT AURINIA
Aurinia is a fully integrated biopharmaceutical company focused
on delivering therapies to treat targeted patient populations that
are impacted by serious diseases with a high unmet medical need.
The Company recently introduced the first FDA-approved oral therapy
indicated for the treatment of adult patients with active lupus
nephritis (LN). Aurinia’s head office is in Victoria, British
Columbia; its U.S. commercial hub is in Rockville, Maryland; and
the Company focuses development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210910005494/en/
Investor and Corporate Contact: Dana Lynch, Corporate
Communications & IR dlynch@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024